Old API Wind-down Ltd - Ordinary Shares ARLZQ

RE:RE:Value of Yosprala

[mjh9413]

Was not too difficult to find numbers.
26MM  secondary protection patient base of which 70% take aspirin. So, each 10% market share is 1.8MM  patients paying possibly $150/mth, so that would translate to GROSS revs of $819MM. Big number, but aspirin component is very large part of cost (even though dedicated supplier as I understand it). Add in manufacturing costs (not marketing) perhaps qtrly NET revs will be 10% of this BIG NUMBER. Not bad if real.
And what do sales people earn. Well it seems about $30MM of Q1's S,G&A was not direct employee costs...so $7MM includes 25 salesforce?? Similarly the $22MM in Q2 includes significant one-time costs ($10MM to Pozen Exec!!) but it seems also a lot (in both qtrs) is in share-based compensation wherein shares allotted are very favorably priced ($2.50 in last qtr I believe). So we have lots of pressure on share price from holders of these, as well as other options and RSU's. My major point is that costs in equiv terms are not bad but in share commitment terms are high!!! But in worst case scenario they pale into insignificance IF $81.9MM/qtr for just 10% market share is a reasonable NET REV on Yosprala. Seems high!!! Anyone?